Edarbi Clo, 98 pcs., 40 mg+12.5 mg, tablets

Prohibited during pregnancy

Prohibited during breastfeeding

Prohibited for children

Allowed for older people

Allowed for liver problems

Allowed for kidney problems

Pathologies of the cardiovascular system occur quite often. Hypertension is especially common and occurs not only in people of retirement age, but also in young people. The disease is easier to treat in the initial stages, which is why it is recommended to undergo systematic medical examinations in order to promptly identify certain changes in the body. Pharmacology provides a fairly significant number of antihypertensive medications that can cope with the manifestations of high blood pressure. The drug "Edarbi" is very popular.

pharmachologic effect

Manufacturer: Taceda Pharmaceuticals USA, USA
Release form: tablets

Active ingredients: azilsartan, chlotalidone

Synonyms: Edarbi

All effects of the drug are provided by its constituent components:

1. Azilsartan is an angiotensin II receptor antagonist, an antihypertensive component.
2. Chlorthalidone is a diazide diuretic.

The main pharmacological effects of the drug are the following:

• preventing the manifestation of the effects of angiotensin II - vasospasm, increased heart rate, increased aldosterone production;
• blocking receptors for angiotensin II in the adrenal glands and blood vessels;
• decreased blood pressure;
• increased excretion of sodium and chlorine in the kidneys;
• increased diuresis.

The hypotensive effect of the drug depends on the dose. The effect of taking a single dosage lasts 24 hours.

Features of the drug "Edarbi"

Often, the recommendations of cardiologists focus on this particular drug, since it is available in tablets, the main active ingredient is azilsartan medoxomil potassium, and is characterized by increased efficiency. The medicine can quickly reduce blood pressure because it is a second-generation receptor antagonist. The drug is used not only to reduce blood pressure, but also in a number of other cases. Indications:

• Hypertensive disease;
• Essential hypertension;
• Heart failure (chronic and acute form)

The drug has different dosages - 20, 40, 80 mg. The drug is considered a combination drug, since it contains a diuretic and medoxomil. The combination of substances provokes a quick effect. The drug is taken once a day to obtain a sustainable result. Contraindications include the inability of pregnant women and nursing mothers to take the product. It is also not recommended to use Edarbi before adulthood. Side effects:

• Dizziness and anemia;
• Too sudden change (decrease) in pressure;
• Nausea, as well as vomiting, diarrhea;
• Itching and rash, muscle spasms;
• Increased fatigue;
• Angioedema, peripheral.

The cost of the drug is 500-650 rubles, so many are looking for an analogue of Edarbi tablets, which had the same indications and composition, but would have a more affordable price.

Edarbi Clo - instructions for use

The drug must be taken once a day without breaks or withdrawal without the consent of the doctor. The initial dose of the drug is 40/12.5 mg. If necessary, the daily amount of the drug can be increased to 40/25 mg.

In accordance with the instructions for use, taking a double dose of Edarbi Clo is prohibited.

The medicine is intended for long-term use, which requires monitoring of the electrolyte composition of the blood. The withdrawal of the drug is carried out gradually.

How to take Edarbi - before or after meals

The medicine should be taken regardless of food and washed down with 100 ml of water. It is recommended to take it at the same time, preferably in the morning.

Doses of the drug should be selected with caution in patients with renal impairment. The most common side effects are dizziness, dyspepsia, increased urea and creatinine levels, and decreased potency. Gout does not develop due to increased concentrations of uric acid, including with long-term therapy.

It is prohibited to prescribe the drug and its full analogues for renal failure, severe forms of diabetes, patients under 18 years of age, pregnant women, hypokalemia, the use of Aliskiren, and liver damage. Caution is necessary when using the drug in patients over 75 years of age, with cardiomyopathies, heart failure, kidney and liver disorders.

Analogues of Edarbi Clo

Complete substitutes for the drug are not produced. The closest in composition is an analogue of one active substance - the antihypertensive monodrug Edarbi, containing only azilsartan.

If a doctor is choosing what can replace Edarbi Clo, the patient’s condition and the market for antihypertensive drugs with a similar mechanism of action should be analyzed. Among such group substitutes that affect angiotensin II receptors, the following drugs are distinguished:

• drugs based on losartan - Vasotens, Cozaar, Lozap, Lorista;
• analogues containing valsartan - Diovan, Valz, Sartavel, Exforge (with amlodipine), Co-Exforge;
• medicines based on telmisartan - Telzap, Micardis, Tanidol, Telpres, Telminorm, Telmista, Telsartan;
• preparations with olmesartan - Cardosal, Olimestra;
• analogues with candesartan - Ordiss, Kandecor, Atakand, Angiakand;
• substitutes based on irbesartan - Aprovel, Irsar, Irbis.

The following modern drugs can be considered analogues of antihypertensive drugs with other mechanisms of action:

• ACE inhibitors, including in combination with diuretics and other active substances - Enalapril (Enap, Renitec), Captopril (Capoten), Lisinopril (Lisoril, Liziprex), Ramipril (Tritace, Hartil), Trandolapril (Tarka), Perindopril (Prestarium, Perineva, Ko‒perineva, Noliprel, Dalneva);
• calcium channel blockers - Amlodipine, Felodipine, Verapamil, Nifedipine, Diltiazem, Lercanidipine (Lerkamen);
• diuretics - Spironolactone, Amiloride, Furosemide, Indapamide, Chlorthalidone, Xipamide, Eplerenone, Triamterene.

The medicine and all its analogues are often combined with other drugs that affect the functioning of the heart - beta blockers (Bisoprolol, Metoprolol), antiplatelet agents, antispasmodics, etc.

List of analogues of Edarbi clo with prices

Edarbi or Edarbi Clo - which is better, what is the difference

Manufacturer: Taceda Pharmaceuticals USA, USA
Release form: tablets

Active ingredient: azilsartan

Synonyms: Edarbi Clo

Edarbi is a monocomponent antihypertensive analogue, which, unlike Edarbi Clo (40 mg +12.5; 25 mg), consists of one active substance, azilsartan, in doses of 20, 40 or 80 mg.

The activity of such a drug is lower, since the composition does not contain a diuretic component, which enhances the effectiveness of antihypertensive therapy.

The medicine is ideal for those patients in whom azilsartan independently allows them to achieve normal blood pressure levels. The reception regimen for these analogues is identical.

Analogues of the drug Edarbi from Russian manufacturers

These are drugs that have a similar composition, as well as specific effects on the body, but have more affordable price parameters. We propose to study similar drugs that are produced by domestic pharmaceutical companies:

• Angiakand. An excellent analogue that quickly copes with chronic heart failure, as well as high blood pressure. It has similar contraindications to Edarbi, since it cannot be used during lactation, pregnancy and under the age of 18 years. The active ingredient is candesartan cilexetil. Before use, it is recommended to consult a doctor regarding dosage. The cost is no more than 320 rubles;
• Oxodolin. The most accessible analogue, which contains the substance in its composition, is chlorthalidone. In addition to quickly lowering blood pressure, additional treatment and prevention of pathologies of blood vessels and the heart are also formed. The cost is no more than 150 rubles, indications, contraindications and mechanics of action on the body are similar to Edarbi;
• Blocktran. Price from 200 rubles, active substance – potassium losartan. Used in the treatment of hypertension, provides a rapid reduction in blood pressure, taken once a day. The dosage is determined individually, depending on the degree of development of the pathology;
• Sartavel is considered the most popular analogue, as it is highly effective and has minimal negative side effects. Dispensed by prescription. The main active ingredient is valsartan. The composition of active components differs significantly from Edarbi, but the mechanics of action on the body remain the same.

These analogues of the drug Edarbi are quite popular, since in addition to an affordable price, they also have decent effectiveness.

Edarbi or Valsacor - which is better?

Manufacturer: KRKA, Slovenia
Release form: tablets

Active ingredient: valsartan

Synonyms: Exforge, Diovan, Valz, Sartavel

Valsacor is one of the most studied analogue drugs of Edarbi Clo. The drug is a monocomponent and is indicated for the treatment of essential hypertension. The strength of the hypotensive effect directly depends on the dosage of the drug.

The effect of taking a single dose appears after 2 hours.

The safety and effectiveness of such a substitute has been proven by clinical studies.

Edarbi or Lozap - which is better?

Manufacturer: Zentiva, Czech Republic
Release form: tablets

Active ingredient: losartan

Synonyms: Lorista, Vasotens, Cozaar

Lozap belongs to the group analogues of Edarbi Clo in tablets. The drug is well tolerated and rarely causes dizziness or fatigue. The drug is often used as part of combination therapy for heart failure, diabetic nephropathies, and also to reduce the risk of stroke in patients suffering from cardiovascular pathologies. This analogue is not used during pregnancy, or in patients under 18 years of age.

Ukrainian analogues of the drug Edarbi

Many Ukrainian analogues of the drug Edarbi have gained significant popularity due to their incredibly affordable price, which does not exceed 150 rubles:

• Advocard is a drug for the prevention and treatment of various heart diseases. Actively copes with the manifestations of arterial hypertension, cardiac failure, ischemia. It has a minimum number of contraindications, the cost is no more than 150 rubles. For correct and quick treatment, it is important to correctly determine the dosage;
• Agent The average cost is 150 rubles, it copes well with numerous vascular and heart diseases, eliminates the manifestations of angina pectoris and hypertension. It has a number of advantages, since it contains components that can become the basis for the prevention of the development of heart diseases;
• Agapurin. This is a full copy of Edarbi in properties. Copes with hypertension, ischemia, irregular heart rhythm and a host of other cardiovascular problems. Price around 100 rubles;
• A-diston. The product costs 60 rubles and is used for mild problems with blood vessels and heart pathologies. The dosage must be agreed with the doctor separately, taking into account the characteristics of the course of the disease;
• Losartan is an affordable drug that is recommended for use in patients with second degree diabetes. Helps reduce the manifestations of renal failure. Side effects: vomiting, itching, rash, diarrhea, etc., are extremely rare.

Edarbi Clo or Lorista - which is better?

Manufacturer: KRKA, Slovenia
Release form: tablets

Active ingredient: losartan

Synonyms: Vasotens, Cozaar, Lozap

Lorista is an imported, cheaper antihypertensive analogue of Edarbi Clo from the group of angiotensin II receptor antagonists. The medicine contains one component and is taken, as a rule, once a day in a dose selected by the doctor. Often this drug is combined with other groups of drugs, including antihypertensives. The use of Lorista during pregnancy and in patients under 18 years of age is prohibited.

Edarbi or Telmisartan - which is better?

Manufacturer: North Star, Russia
Release form: tablets

Active ingredient: telmisartan

Synonyms: Telzap, Mikardis, Tanidol, Telpres, Telminorm, Telmista, Telsartan

Telmisartan is a new and effective antihypertensive drug. The peculiarity of this group Russian analogue of Edarbi Clo is that the main metabolism is carried out in the liver, so the drug can be used in patients with kidney pathologies without dose adjustment.

Since the half-life of telmisartan and its analogues is longer than other active substances in this group, the duration of the hypotensive effect will be more than 24 hours.

The drug allows you to effectively control the morning increase in blood pressure, which is an excellent prevention of heart attacks and strokes. Telmisartan is not used to treat patients under 18 years of age, as well as pregnant women.

Belarusian generics

Generics are substitutes for Edarbi, which have the same composition of the drug, but have a completely different name. Products from Belarusian manufacturers are especially popular, since they were able to accurately replicate the composition:

• Diovan. The cost is no more than 300 rubles, it has a completely identical composition, mechanics of action, indications and contraindications, like Edarbi. Recommended for use in the early stages of hypertension. Available in various dosages, the therapeutic effect occurs within two weeks of continuous use of the drug;
• Nortivan. An exact copy of the drug, cost 320 rubles. The dosage is determined by the doctor individually. The blood pressure level decreases without changing the heart rate. After four hours after administration, the maximum effect is observed. Actively used for chronic cardiac pathologies.

Edarbi or Dalneva - which is better?

Manufacturer: KRKA, Slovenia
Release form: tablets

Active ingredient: perindopril, amlodipine

Synonyms: Perindopril, Amlodipine

Dalneva is a combined analogue for the hypotensive effect, containing the ACE inhibitor perindopril and the calcium channel blocker amlodipine. The medicine can cause a number of side effects - drowsiness, headaches, palpitations, visual disturbances, tinnitus, swelling of the legs, itching of the skin. This analogue is not used in patients with impaired renal function, during pregnancy, or in patients under 18 years of age. Prescribing the drug to elderly patients requires a dose reduction and caution during use.

Edarbi Clo, 98 pcs., 40 mg+12.5 mg, tablets

Suction

Azilsartan medoxomil is a prodrug. After oral administration, it is converted into the pharmacologically active metabolite azilsartan during absorption from the gastrointestinal tract under the action of the enzyme carboxymethylenebutenolidase in the intestines and liver.

The estimated absolute bioavailability of azilsartan medoxomil when administered orally is approximately 60% based on plasma concentration profiles. Cmax of azilsartan in blood plasma is achieved on average within 1.5–3 hours after taking the drug orally. Food intake does not affect the bioavailability of azilsartan.

Distribution

Vd of azilsartan is about 16 l. Azilsartan binds to blood plasma proteins (more than 99%), mainly to blood plasma albumin. The binding to plasma proteins remains constant when the concentration of azilsartan in the blood plasma significantly exceeds the range achieved when taking recommended doses.

There are no data on the use of the drug during pregnancy and breastfeeding. Azilsartan crosses the placenta of pregnant rats and is excreted into the milk of lactating rats (see “Use during pregnancy and lactation”).

Animal studies with radioactive tracers have shown that the amount of azilsartan that penetrates the BBB is minimal.

Metabolism

Azilsartan is metabolized to two primary metabolites primarily in the liver. The main metabolite in blood plasma is formed by O-dealkylation and is designated as metabolite M-II, the minor metabolite is formed by decarboxylation and is designated as metabolite M-I. The AUC values ​​for these metabolites in humans are respectively 50% and less than 1% compared to azilsartan. M-I and M-II do not affect the pharmacological activity of Edarbi®. The main enzyme responsible for the metabolism of azilsartan is the CYP2C9 isoenzyme.

Removal

Azilsartan and its metabolites are excreted from the body, both through the intestines and the kidneys. Studies have shown that after oral administration of azilsartan medoxomil, about 55% (mainly in the form of metabolite M-I) is found in the feces and about 42% (15% in the form of azilsartan, 19% in the form of metabolite M-II) in urine . T1/2 of azilsartan is about 11 hours and renal clearance is about 2.3 ml/min. Css of azilsartan is achieved within 5 days, and its accumulation in the blood plasma does not occur with a single daily use.

Linearity/nonlinearity

The pharmacokinetics of azilsartan in azilsartan medoxomil are dose proportional over a dose range of 20 to 320 mg following single or multiple oral doses.

Pharmacokinetics in special groups

Children.

The pharmacokinetics of azilsartan in children under 18 years of age has not been studied.

Elderly patients.

The pharmacokinetics of azilsartan in young (18–45 years) and elderly (65–85 years) patients does not differ significantly.

Kidney failure.

In patients with mild, moderate and severe renal impairment, AUC was increased by +30, +25 and +95%, respectively. An increase in AUC was not observed in patients with end-stage renal disease on hemodialysis. Clinical data on pharmacokinetics in patients with severe or end-stage renal failure are not available.

Azilsartan is not removed from the systemic circulation by hemodialysis.

Liver failure.

Use of Edarbi® for more than 5 days in patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment leads to a slight increase in AUC (1.3–1.6 times, respectively) ). The pharmacokinetics of Edarbi® in patients with severe (class C on the Child-Pugh scale) degree of liver failure have not been studied.

Gender.

The pharmacokinetics of azilsartan in men and women is not significantly different. No dose adjustment is required depending on gender.

Race.

The pharmacokinetics of azilsartan do not differ significantly depending on the race of patients.